contact us    log-in   
Portfolio

These companies make good things happen through meaningful transformation of ideas from conception to commercialization. They have the passion and commitment it takes to turn entrepreneurial vision into market reality. As a result, people have better lives. We like that. We’re proud of every company in our portfolio and grateful for the opportunity to be part of their story.  
 
 


Alexza Pharmaceuticals [NASDAQ: ALXA]

Alexza Pharmaceuticals is focused on the development and manufacture of novel proprietary products using its proprietary Staccato®system which vaporizes an excipient-free drug to form an orally inhaled aerosol.
 
 


Argos Therapeutics [NASDAQ: ARGS]

Argos Therapeutics’ "Arcelis" technology usesRNA-loaded dendritic cells and advanced manufacturing processes to provide aplatform to tackle virtually all forms of cancers and infectious diseases. 
 
 


Aurinia Pharmaceuticals Inc. [VAN: AUP.V]

Aurinia Pharmaceuticals is a clinical stage pharmaceuticalcompany focused on the global nephrology market. Its lead drug, voclosporin, isa novel calcineurin inhibitor being developed for the treatment of LupusNephritis.
 
 


BAROnova

BAROnova is developing a novel, non-surgical device for thetreatment of obesity. It consists of a TransPyloric Shuttle device that isinserted into the stomach through the mouth using a simple, 10-minuteendoscopic procedure.
 
 


Cardiac Dimensions

Cardiac Dimensions is developing a minimally invasiveimplantable product to treat mitral valve regurgitation associated withcongestive heart failure.
 
 


DC Devices

DC Devices is a private medical device company based in Massachusetts developing a catheter-delivered implant for treating diastolic heart failure.
 
 


Engene

Engene has a novel proprietary method to deliver therapeutic proteins to the gastrointestinal (GI) tract to treat diseases of the GI tract as well as diseases that may be attenuated via the actions of therapeutic proteins at the GI tract.
 
 


Lorus Therapeutics [TOR: LOR.TO]

Lorus is a clinical stage cancer drug development company.
 
 


NephroGenex [NASDAQ: NRX]

NephroGenex is a biotechnology company developing advancedtreatments for kidney disease.
 
 


Spinal Kinetics

Spinal Kinetics has developed and commercialized a unique technology designed to replicate the natural vertebral disc in its structure and physiologic range of motion in all planes, including axial compression.
 
 


Thrasos Innovation

Thrasos is focused on the discovery and development oftargeted therapies for the prevention and treatment of kidney disease. 
 
 


Vendorlink dd]

Vendorlink.ca is a provider of web-based vendor management solutions for Canadian hospitals.
 
 


Alveolus - Exited

Alveolus, developer of next generation non-vascular interventional stent technology for use in the lungs was acquired by Merit Medical Systems Inc. in February 2008.
 
 


Archemix - Exited

In November 2010 Archemix agreed to sell all of its hemophilia-related assets to Baxter International Inc. in deal worth up to $305 million. 
 
 


Cardiovascular Systems - Exited [NASDAQ: CSII]

Cardiovascular Systems is a medical device company that develops and commercializes interventional technologies for the treatment of cardiovascular disease.
 
 


Ception Therapeutics - Exited

Ception Therapeutics was acquired by Cephalon Inc. in March 2010 in a deal worth $350 million plus significant future millstones. Cephalon was subsequently acquired by Teva in 2011.
 
 


Corus Pharma - Exited

Corus Pharmaceuticals, developer of Aztreonam for treatment of cystic fibrosis and Lidocaine for treatment of oral corticosteroid dependent asthma was acquired by Gilead in August 2006.
 
 


Depomed - Exited [NASDAQ: DEPO]

Lumira Capital led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005.
 
 


Guava Technologies - Exited

Guava Technologies was acquired for $22.6 million by Millipore Inc. in February, 2009. 
 
 


ISTA Pharmaceuticals - Exited [NASDAQ: ISTA]

From the time we invested in 2002 to our exit in 2006 ISTA launched three products in the United States to treat diseases of the eye.
 
 


KAI Pharmaceuticals - Exited

KAI Pharmaceuticals, developer of novel therapeutics for kidney disease was acquired by Amgen in 2012 for US$315 million.
 
 


MAKO Surgical - Exited [NASDAQ: MAKO]

Lumira was an early investor in MAKO Surgical prior to its IPO. MAKO markets both its RIO Robotic-Arm Interactive Orthopedic system and proprietary implants for minimally invasive orthopedic knee procedures.
 
 


Morphotek - Exited

Morphotek, developer of therapeutic antibodies for the treatment of cancer, inflammatory and infectious diseases was acquired by Eisai in April 2007.
 
 


Pharmasset - Exited [NASDAQ: VRUS]

Pharmasset was acquired by Giliad in 2011 for $11 Billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
 
 


Renovis - Exited [NASDAQ: RNVS]

Lumira Capital exited public company Renovis, developer of therapeutics for Neurological and inflammatory disease fields in 2005 and 2006.
 
 


Resonant Medical - Exited

Resonant Medical, developer of 3D ultrasound image-guided radiotherapy products was acquired by Elekta in May of 2010 for $30 million in cash.
 
 


U-Systems - Exited

Automated Breast Ultrasound company U-Systems was acquired by GE healthcare in late 2012.
 
home   |   about us   |   our team   |   our portfolio   |  login
privacy policy | terms of use
©Lumira Capital Corp. 2012